MedPath

Randomised double-blind trial of combination antibiotic therapy in rheumatoid arthritis

Phase 1
Conditions
Patients with medical diagnosis of Rheumatoid Arthritis
Registration Number
EUCTR2004-004893-96-GB
Lead Sponsor
Hammersmith Hospitals NHS trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Age 18 -30
Classical Rheumatoid Arthritis
Erosions on joint radiographs
Rheumatoid factor posiyive
Disease duration>6 months
Active disease 6 or more inflamed joints: ESR>20mm/hr or CRP>12 mg/ml
Failed on methotrexate> or= 7.5 mg/week
No anti-TNF therapy for at least three months
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Severe disease
Chronic recurrent infection
Immunodeficiency
Malignancy
Inflammatory bowel disease
Other diarrhoeal states
Other major illnessess
History of adverse reactions to tetracycline, clindamycin or similar antibiotics
Pregnancy or lactation

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To perform a double-blind, randomised, controlled trial comparing the effect of intravenous clindamycin plus oral tetracycline with placebo as an addition to conventional treatment(second line therapy with or without prednisolone) with placebo in the management of active rheumatoid arthritis.;Secondary Objective: ;Primary end point(s): The primary outcome measure will be the achievement of an ACR20% response in 6 months
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath